Human vascular endothelial cells (ECs) are categorized into two groups; pro-stenotic (Type-I) and anti-stenotic (Type-II) ECs, and one of the master genes for a stress-induced "Type-II-to-Type-I" degeneration is Regulator of G-protein signaling 5 (RGS5). Here we show that miR-10b is a crucial downstream mediator in RGS5-dependent degeneration.
Introduction
Ischemic heart disease and brain stroke are the top two causes of death in the world. The major pathological basis for these diseases is atherosclerosis, where hardening and narrowing (i.e. stenosis) of the arteries causes insufficient blood supply, and thus, impairs the functions of target organs/tissues including the heart, brain, lung and kidneys.
Atherosclerosis begins with damage to vascular endothelial cells (ECs), which then leads to the formation of neointima by triggering the hyper-proliferation of vascular smooth muscle cells (SMCs). In addition to atherosclerosis, other pathological situations also induce stenosis of the arteries. For example, patients with systemic sclerosis often suffer from fatal ischemic organ failures due to serious stenosis of the arteries in the lungs and kidneys, where onion skin-like intimal thickening is observed via hyper-proliferation of SMCs. Simple mechanical damage to ECs even induces severe stenosis of the arteries; for example, restenosis after stent placement therapy in humans and wire injury operation in mice as its experimental model.
The common pathological feature of arterial stenosis is the hyper-proliferation of SMCs. Although the majority of SMCs reside within the tunica media of the arteries, a small number of them locate within the tunica intima underneath vascular endothelial cells (ECs). When ECs are damaged or removed, SMCs in tunica media start to migrate to tunica intima, where they proliferate without control. The hyper-proliferated SMCs create neointima, which narrows the arterial lumen and reduces blood flow. Although there had been a longstanding dispute over the involvement of ECs in the etiology of ischemia, the controversy has been settled by a series of integrated studies using a wide variety of commercially available primary cultured human ECs and multiple lines of human pluripotent stem cell-derived ECs (1) (2) (3) . In those studies, it was shown that human ECs are classified into two types according to their effects on the proliferation of SMCs.
While commercially available primary cultured ECs are exclusively as pro-proliferative ECs (Type-I) (1) , freshly prepared ECs from human embryonic stem (ES) cells are classified as anti-proliferative ECs (Type-II). In addition, these Type-II ECs are converted into Type-I ECs after repetitive subcultures or oxidative stresses (1) . The master gene for phenotype conversion from anti-proliferative Type-II into pro-proliferative Type-I ECs is
Regulator of G-protein signaling 5 (RGS5) (1) : freshly prepared ECs are negative for RGS5 expression while various kinds of stresses including oxidative stress and repetitive subcultures induce RGS5 expressions, and therefore, RGS5 shuts down the anti-proliferative functions of Type-II ECs. By contrast, RGS5 protein expressions are significantly up-regulated in ECs of pathological vessels as observed in the cases of hypertension(1), arteriosclerosis (1) , systemic lupus erythematosus (1) and scleroderma (4, 5) . Furthermore, transplantation experiments verified the "pro-stenotic" and "anti-stenotic" properties of Type-I and Type-II ECs, respectively (6) . In Figure 1A , the concept for Type-I versus type-II categorization of ECs is summarized. However, the crucial molecules that are involved in the regulation of Type-I/Type-II phenotypes of ECs at the downstream of RGS5 remain elusive.
It is widely accepted that transforming growth factor β (TGF-β) transmits a robust and potent inhibitory signal against SMC proliferation (7) (8) (9) (10) (11) . Although the expression level of TGF-β defines the strength of growth inhibitory potential in most cases, the other factors also determine the efficacy of TGF-β signaling. For example, Latent transforming growth factor-β binding protein 1 (LTBP1) plays an essential role in the induction of TGF-β mediated quiescence of hematopoietic stem cells (HSCs)(12). Therefore, expression levels as well as activities of TGF-β and LTBP1 should be precisely evaluated to understand the molecular mechanism for Type-I/Type-II quality control of ECs.
Here we showed that miR-10b, which is known to be involved in malignant progression of solid tumors(13, 14), is a crucial downstream mediator of RGS5-dependent "Type-II-to-Type-I" phenotype conversion of ECs. We also showed miR-10b reduces the expression level of LTBP1 protein, thus could suppress the anti-proliferative ability of Type-II ECs. We further demonstrated in vivo relevance of miR-10b in the pathophysiology of atherosclerosis by showing that miR-10b knockout mice become resistance to the development of atherosclerosis. Possible link between vascular injuries and malignant progression of tumors is also discussed.
RESULTS

miR-10b is the crucial downstream mediator for RGS5-dependent EC phenotyping
To understand the molecular events involved in phenotype regulation of ECs at the downstream of RGS5, we first examined the expression profile of TGF-β. Although TGF-β is known as the major cytokine to suppress the proliferation of suppression of SMCs(7-11), TGF-β mRNA as well as TGF-β protein did not show Type-I/Type-II categorization-dependent expression profiles (Supplemental Figure S1A, S1B).
Moreover, we found no correlations between the LTBP1 mRNA expression profile and
Type-I/Type-II categorization (Supplemental Figure S2 ). Therefore, the proliferation of SMCs is regulated by other mechanisms than mRNA expression-regulating system for TGF-β and LTBP1.
Since our previous microarray analyses using exon probes (GEO Accession ID: GSE60999 and GSE61000) revealed that RGS5 was the only protein-coding gene that showed EC categorization-dependent expression profiles(1), we hypothesized that certain non-coding RNAs would be involved in regulating Type-I/Type-II quality control of ECs. From this standpoint, we performed miRNA array analyses using various lines of Type-I and Type-II human ECs. We obtained eight candidate miRNAs, which showed statistically significant differences (P < 0.01) in their expression profiles between the two groups ( Figure 1B ). They consisted of hsa-miR-10b, hsa-miR-196b-5p, hsa-miR-1973, hsa-miR-4485-3p, which showed Type-I-dominant expression patterns, and hsa-miR-199b-5p, hsa-miR-199a-5p, hsa-miR-199a-3p, hsa-miR-214-3p, which showed Type-II-dominant expression patters. Among these candidates, we focused on has-miR-10b-5p (hereinafter referred to as miR-10b) since its expression profile exactly coincided with the mode of Type-I/Type-II categorization as supported by the lowest P value (P = 0.000186). To verify whether miR-10b was involved in the regulation of Type-I/Type-II quality control of ECs at the downstream of RGS5, we examined the effects of overexpression and knockdown of miR-10b. We showed the enforced expression of miR-10b in Type-II ECs suppressed their anti-proliferative function ( Figure   1C ), while treatments with a miR-10b inhibitor(15) deteriorated pro-proliferative capacities of Type-I ECs ( Figure 1D ). We also confirmed that enforced expressions of RGS5 in Type-I EC induced up-regulation of miR-10b ( Figure 1E ). Therefore, miR-10b is a crucial downstream mediator in RGS5-dependent Type-I/Type-II quality control of ECs.
Stress-dependent induction of miR-10b in ECs
Since oxidative stresses up-regulate endothelial RGS5 expressions(1), we examined the effects of various reactive oxygen species (ROS)-producing vasotoxic stimuli on the expression of miR-10b. We found that γ-irradiation(16) (Figure 2A It is well known that miRNAs are incorporated into exosomes and transmit various biological effects to the target cells. Therefore, we collected exosomes from Type-I and Type-II ECs (Supplemental Figure S3 ) and examined the expression levels of miR-10b.
We found that Type-I EC's exosomes contained higher amounts of miR-10b than Type-II EC's one ( Figure 2D ), consistently with the finding that Type-I ECs expressed higher levels of intracellular miR-10b ( Figure 1B ). To verify in vivo relevance of the expression of exosomal miR-10b in the context of vascular stresses/damages, we performed wire injury (WI) operations in murine femoral arteries and measured the levels of miR-10b expressions within blood plasma. We found that miR-10b expression levels in circulating blood exosomes were up-regulated after vascular damages ( Figure 2E ). Therefore, miR-10b expression levels are up-regulated under EC-damaging circumstances both in vitro and in vivo.
miR-10b knockout mice are resistant to atherosclerosis development
To further assess pathological relevance of up-regulated miR-10b expressions with vascular damages, we generated miR-10b knockout (KO) mice (Supplemental Figure S4 ).
To evaluate the involvement of miR-10b in the development of atherosclerosis, wild type (WT) and two lines of miR-10b KO mice were subjected to experimental atherosclerosis.
Five-week-old mice, which were fed by high-fat, high-cholesterol diet supplemented with cholic acid, were subjected to partial carotid ligation(20). After three weeks, the conditions of treated and non-treated carotid arteries were examined by ultrasonography.
We found that treated arteries of WT mice exclusively showed stenotic features ( Figure   3A 
The target of miR-10b is LTBP1 in Type-II EC-mediated growth suppression of SMCs
To identify the target of miR-10b in Type-I/Type-II quality control of ECs, we searched the candidate target mRNAs by using miRDB software(21, 22). As shown in Supplemental Figure S5 , we obtained 232 candidates as a target mRNA for miR-10b.
Among these candidates, we focused on LTBP1 ( Figure 4A ) since it is known to play an essential role in transducing TGB-β-dependent growth-inhibitory signaling in HSC niche(12). TGF-β is secreted in a latent form and deposited to extracellular matrix via LTBP1, thus making a latent TGF-β/LTBP1 complex. When latent TGF-β is cleaved by specific proteases such as αV Integrins, active TGF-β is generated and released from the complex. Therefore, LTBP1 provides an effective platform for a rapid increment in the local concentration of active TGF-β at the site of action, serving as the key factor in the biological effects of TGF-β in certain cases(12, 23, 24). Hence, we examined the Figure S6B ). On the other hand, LTBP3, which could bind latent TGF-β(25), and LTBP4, which scarcely bind latent TGF-β either(25, 26), showed Type-I/Type-II categorization-associated expression profiles (Supplemental Figure S6B ).
However, an enforced expression of miR-10b as well as knockdown of miR-10b expression did not affect the expression of either LTBP3 or LTBP4 protein (Supplemental Figure S6C ). These findings indicate that miR-10b specifically targets the expression of LTBP1 protein.
To verify the involvement of TGF-β-dependent signals in Type-II EC-mediated growth suppression of SMCs, we inhibited the TGF-β signaling in Type-II EC-SMC interactions. When we added LY2157299, a selective small molecule TGF-β receptor I kinase, to the EC-SMC co-culture system, anti-proliferative capacities of Type-II ECs were reduced in a dose dependent manner ( Figure 4E ). Hence, TGF-β signaling was involved in executing of the anti-proliferative function of Type-II ECs against SMCs.
Flow cytometric analyses further demonstrated that the number of SMCs with phosphorylated SMAD2/3, which are the crucial downstream effectors in the intracellular signal transduction after TGF-β receptor activations, was up-regulated by co-culture with Type-II ECs ( Figure 4F ). Moreover, nuclear localized SMAD3 in Type-II EC-co-cultured SMCs were determined by immunostaining studies ( Figure 4G ).
Collectively, LTBP1 is a crucial target of miR-10b in "Type-II-to-Type-I" degeneration of ECs, where loss of LTBP1 protein hampers locally concentrated existence of active TGF-β at EC-SMC interaction sites, and thus, deteriorates the suppressive activities of Type-II ECs against the proliferation of SMCs.
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Trans effects of exosomes of Type-I and Type-II ECs
A wide variety of cells secret exosomes and exert diverse biological effects by conveying miRNAs(27) and proteins(28) to adjacent and distant cells. Therefore, we examined the trans effects of exosomes that were secreted by Type-I and Type-II ECs, respectively.
Firstly, we examined whether miR-10b, which is induced specifically in Type-I ECs, could be transferred to Type-II ECs via an exosomal route to reduce the expression levels of LTBP1 protein in Type-II ECs, and thus, convert the anti-stenotic Type-II ECs into pro-stenotic Type-I ECs. We found that treatments of Type-II ECs with "Type-I EC exosomes" reduced the expression levels of LTPB1 protein in Type-II ECs ( Figure 5A) and also abolished the ability of Type-II ECs to suppress the proliferation of SMCs ( Figure 5B ). Hence, "Type-I EC exosomes" exert a trans effect on Type-II ECs by hampering their anti-proliferative abilities via miR-10b transfer to reduce the expression of LTBP1 protein, and thus, inducing "Type-II-to Type-I" conversion.
Next, we examined the effects of "Type-II EC exosomes". Since Type-II EC exosomes were negative for miR-10b expression, it does not seem possible for them to exert trans effects via exosomal transfer of miR-10b to adjacent cells. By contrast, Type-II EC exosomes were positive for LTBP1 protein expression, and thus, they might possibly exert trans effects via exosomal transfer of LTBP1 protein to strengthen TGF-β-dependent growth-inhibitory signals. To validate this hypothesis, we examined the distribution pattern of LTBP1 protein in murine arteries. ECs lining at the luminal surface of the normal arteries exclusively expressed LTPB1 protein ( Figure 5C upper, arrow heads), which is consistent with the in vitro finding that healthy Type-II ECs expressed high levels of LTBP1 protein ( Figure 4B ). Although cultured SMCs were 1 2 negative for LTBP1 protein expression (Supplementary Figure S2B ), LTBP1 protein was sporadically detected in SMCs in tunica media ( Figure 5C upper, arrows). Interestingly, LTBP1 protein became undetectable throughout the vascular walls when ECs had been mechanically removed by WI operation (Figure 5C , lower), indicating that LTBP1 protein in the vascular walls was primarily produced by ECs including the one detected in SMCs at tunica media. Since the exosomes of healthy Type-II ECs, but not those of degenerative Type-I ECs, expressed high levels of LTBP1 protein ( Figure 5D ), we hypothesized that LTBP1 protein was transferred from ECs to SMCs via an exosomal route in healthy arteries. To validate this hypothesis, we cultured SMCs with or without Type-II EC exosomes and examined whether SMCs became positive for LTBP1 protein expression. As shown in Figure 5E , SMCs that were cultured in the presence of Type-II EC exosomes, but not in the presence of Type I EC exosomes or without adding exogenous exosomes, became positive for LTBP1 protein expression. Therefore, healthy Type-II ECs, but not degenerative Type-I ECs, can transfer LTPB1 proteins to SMCs via exosomes.
Finally, we evaluated the pathological relevance of altered LTBP1 protein expressions in the development of atherosclerosis by performing immunostaining studies using the arteries of WT and miR-10b KO mice that were subjected to experimental atherosclerosis. In atherosclerotic arteries of WT mice ( Figure 5C with miR-10b expressions and susceptibility to atherosclerosis.
DISCUSSION
In the current study, we unraveled the molecular events involved in the Type-I/Type-II quality control of ECs ( Figure 6 ). In healthy arteries, ECs express LTBP1 proteins at high levels, some of which are simply secreted to extracellular spaces and some of which are transferred to SMCs via exosomes. Owing to abundant LTBP1 proteins that are continuously supplied by healthy ECs, active TGF-β exists stably in a locally concentrated manner at the site of EC-SMC interactions in tunica intima. Then, locally concentrated active TGF-β stably transmit potent growth-inhibitory signals against SMCs, thus preventing the development of neointima for the homeostatic maintenance of vascular structures. When ECs are damaged by noxious stimuli, however, Type-II ECs are degenerated into Type-I ECs. In the degenerative Type-I ECs, the expression of miR-10b is induced at the downstream of RGS5 and, as a result, the expression levels of LTBP1 protein are down-regulated. Moreover, Type-I ECs secret miR-10b high exosomes to neighboring miR-10b low /LTBP1 high Type-II ECs to convert them into miR-10b high /LTBP1 low Type-I ECs. Therefore, the process of "Type-II-to-Type-I" degeneration of ECs will be accelerated and the damaged arteries will undergo stenotic changes via neointima formation
The molecular mechanism of Type-II EC-mediated growth inhibition of SMCs is growth inhibition of stem cells in those cases. By contrast, TGF-β protein is produced by diverse cells in the bone marrow, and thus, the expression level of TGF-β cannot be a key element for the determination of growth-suppressive potentials. Since the half-life of active TGF-β1 in the blood plasma is considerably short (ca. 2 min)(31), a certain system to stabilize TGF-β signaling is required for the formation of stem cell niches in bloodstream-rich organs such as the bone marrow. It is known that latent TGF-β1 makes a complex with LTBP1 under physiological conditions, and thus, obtain a greatly extended blood plasma half-life (> 100 min)(32). Hence, LTBP1 protein works as a crucial determinant for the formation of the NSC-based HSC niche in the bone marrow. Since
ECs are constantly exposed to bloodstream, it would be highly reasonable that ECs employ LTBP1 as in the case of NSC-based HSC niche for stable implementation of their growth-inhibitory functions to protect injured arteries from undergoing ischemic changes.
Ischemic heart disease is the leading cause of death in the world. Although anticholesteremic agents have provided beneficial outcomes, there are still a number of refractory cases. For example, disseminated atherosclerotic changes are commonly detected in the coronary arteries in patients with diabetic angiopathy, which are resistant to anticholesteremic drug treatments. To develop effectual therapeutic agents for such cases, it is important to elucidate the detailed molecular basis for Type-I/Type-II quality control of ECs. The current study is grounded on our unique finding that we obtained from the analyses regarding human ES/iPS cell-derived ECs, by which the existence of anti-proliferative Type-II ECs were for the first time shown (1) . Extending our previous achievement to identify RGS5 as a master gene responsible for "Type-II-to-Type-I" 1 5
conversion of ECs, we have determined miR-10b as the crucial downstream mediator for quality degradation of ECs. It is reported that the miR-10b expressions in aortic blood plasma are elevated in patients of coronary artery disease with low collateral capacity(33).
Our finding that miR-10b expressions in blood plasma exosomes were elevated in mice with arterial injuries ( Figure 2F ) is consistent with that finding. We further showed the pathological significance of miR-10b: lack of miR-10b expression effectively attenuates the development of atherosclerosis even in the presence of hypercholesterolemia.
Therefore, screening miR-10b-targetting agents would be of use for the therapeutic development of ischemic diseases of various causes.
Pathological impact of miR-10b has been studied intensively in the field of cancer: miR-10b is shown to be involved in malignant progression of glioblastoma multiforme(13) and invasive breast cancer(14). It might be possible that accumulated miR-10b in the circulating blood as a result of miR-10b high exosome secretion by injured ECs promotes malignant progression of cancer. Metabolic syndrome increases risk of cancer via multiple pathways including insulin/insulin-like growth factor (IGF) system, estrogen and pro-inflammatory cytokines(34). Our finding proposes an additional mechanism for the enhanced cancer progression in metabolic syndrome: vascular damages stimulate the emergence miR-10b high pro-proliferative Type-I ECs, which then disseminate miR-10b high exosomes throughout the body via circulating blood and thus enhance malignant progression of cancers. In this sense, miR-10b would provide a promising target for drug discovery in preventing metabolic syndrome-associated cancer progressions. Hamamatsu, Japan) by electroporation was performed as described previously (41) . After the electroporated oocytes were cultured overnight in vitro, two-cell embryos were transferred into the oviducts of pseudopregnant ICR females (CLEA Japan Inc., Tokyo, Japan). Tail genomic DNA of offsprings was isolated using standard methods. The genomic sequence at miR-10b gene locus was amplified by PCR using a forward primer (5'-ACCATCTCTGAAAGCCAGGC-3') and a reverse primer (5'-TGGAGCTTTCTGGCCTTTCA-3'). The mutation was confirmed by Sanger sequencing.
All mice were housed in air-conditioned animal rooms at an ambient air temperature of 22 ± 2ºC and relative humidity of 50 ± 15%, under specific pathogen-free conditions with a 12-h light/dark cycle (8:00 to 20:00 light period). They were fed a standard diet (CE-2, CLEA Japan, Inc., Tokyo Japan) with free access to drinking water. All animal To do multiple comparison (for Fig. 2E, Fig. 3C, Fig. 4E , F and Fig. 5B ), Tukey's HSD (honest significant difference) test was used, following to Bartlett test for checking of their homogeneity of variances. Box plot (Fig. 1C, 1D, 1E, Fig. 2, Fig. 5B) 
